Grant from the U.S. Food and Drug Administration will span three years and include evaluations for more than 200 nominated substances.

Latest renewal allows for up to $5 million per year over five years, and will help M-CERSI further advance its mission to promote the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.

Dr. James Polli’s extraordinary accomplishments in the field of regulatory science make him a UMB Champion of Excellence.

Third-year student pharmacists take the gold for their proposal to develop a transparent tracking system for emerging CAR T-cell gene therapies.

Researchers discuss how to leverage a variety of dissolution and translational modeling strategies to ensure patients continue to have access to safe, effective medications.

First-ever undergraduate competitor takes the gold for project to develop a universal labeling system for hazardous drugs.

Researchers from academia, government, and industry examine both established and emerging techniques to detect protein aggregation in biologic drug products.

Researchers across academia, government, and industry explore how real world evidence can be harnessed to create a national evaluation system and improve the safety and effectiveness of medical devices.

Fourth annual M-CERSI “America’s Got Regulatory Science Talent” competition awards third-year student pharmacists first prize for novel solution to improve FDA’s post-marketing surveillance program.

More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.

Researchers from academia, government, and industry examine benefits and new methods associated with emerging technology.